PMID: 3319640Jan 1, 1987Paper

Comparison of nicardipine and propranolol in the treatment of mild and moderate hypertension

European Journal of Clinical Pharmacology
V A NaukkarinenS Sarna

Abstract

In a double-blind controlled trial 22 patients with mild or moderate essential hypertension were treated with nicardipine 30 mg t.d.s. and 19 patients with propranolol 80 mg t.d.s. as monotherapy for 24 weeks. Blood pressure in both groups at the end of trial was equally and significantly reduced; systolic pressure 22.2 mmHg and diastolic pressure 15.5 mmHg in the supine position, and 24.4 mmHg and 18.4 mmHg, respectively, in the standing position in those on nicardipine, and by 23.7 and 16.2 mmHg and 28.0 and 19.2 mmHg, respectively, in the propranolol group. There was an initial increase in heart rate in the nicardipine group, but the rise was only moderate (3 beats/min supine p = 0.3219, and 7 beats/min standing, p = 0.0203) at the end of the 24 weeks. In the propranolol group heart rate was reduced markedly. Adverse effects occurred in 77% of patients on nicardipine and in 63% of those on propranolol, and there were no unexpected findings. The effects were mild in both groups and did not lead any patient to stop medication. One patient on propranolol was withdrawn from the trial because of poor blood pressure control and suspected angina pectoris after 5 weeks on active medication. There were no significant changes in blood...Continue Reading

References

Jan 1, 1985·Journal of Cardiovascular Pharmacology·A Lehtonen
Jan 25, 1985·The American Journal of Cardiology·B F Robinson
Jun 1, 1985·Archives of Internal Medicine·M H Weinberger
May 10, 1986·Lancet·J C Kingswood, F D Thompson
Jan 1, 1986·European Journal of Clinical Pharmacology·R A GreenbaumT R Evans
Jan 1, 1985·British Journal of Clinical Pharmacology·J Asplund
Jan 1, 1985·British Journal of Clinical Pharmacology·S H TaylorB Silke
Aug 1, 1985·The American Journal of Cardiology·J S GelmanC J Pepine
Jan 1, 1985·British Journal of Clinical Pharmacology·S H TaylorB Silke
Mar 1, 1985·The American Journal of Cardiology·C R LambertC J Pepine
Jan 1, 1985·British Journal of Clinical Pharmacology·D J GrahamD Freedman
Jan 1, 1985·British Journal of Clinical Pharmacology·B C CampbellW S Hillis
Oct 18, 1985·JAMA : the Journal of the American Medical Association·T A MiettinenS Sarna
Jan 1, 1982·Journal of Cardiovascular Pharmacology·B F Johnson
Jan 1, 1982·Journal of Cardiovascular Pharmacology·M H AldermanT K Davis
Jan 1, 1983·Journal of Cardiovascular Pharmacology·P van Brummelen
Sep 1, 1984·Journal of Cardiovascular Pharmacology·M F RousseauH Pouleur
Dec 23, 1982·The New England Journal of Medicine·E Braunwald
Jul 21, 1984·British Medical Journal·D G BlackJ D Swales
Nov 1, 1980·The American Journal of Medicine·A Helgeland
Jan 1, 1982·British Journal of Clinical Pharmacology·A LehtonenJ Niskanen
May 1, 1980·Clinical and Experimental Pharmacology & Physiology·K SatohN Taira
May 1, 1980·Scandinavian Journal of Clinical and Laboratory Investigation·O WiklundL Wilhelmsen

❮ Previous
Next ❯

Citations

Nov 18, 2003·Diabetes, Obesity & Metabolism·E Bøg-HansenL Råstam
Nov 19, 2011·Pharmacognosy Reviews·Nahida Tabassum, Feroz Ahmad

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.